{"id":"long-acting-insulin","safety":{"commonSideEffects":[{"rate":null,"effect":"Hypoglycemia"},{"rate":null,"effect":"Injection site reactions"},{"rate":null,"effect":"Weight gain"},{"rate":null,"effect":"Lipodystrophy"}]},"_chembl":{"chemblId":"CHEMBL1201631","moleculeType":"Protein"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Long-acting insulins are designed to be absorbed slowly and provide steady insulin levels for approximately 24 hours or longer, reducing the need for multiple daily injections. They work by binding to insulin receptors on muscle and fat cells, facilitating glucose uptake and storage, thereby maintaining stable blood glucose levels throughout the day and night.","oneSentence":"Long-acting insulin provides sustained glucose control by mimicking the body's basal insulin secretion over an extended period.","_ai_confidence":"medium"},"_scrapedAt":"2026-03-27T23:52:46.416Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Type 1 diabetes mellitus"},{"name":"Type 2 diabetes mellitus"}]},"trialDetails":[{"nctId":"NCT04542148","phase":"PHASE2","title":"Glycemic Control After Antenatal Corticosteroids in Women With Pregestational and Gestational Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-02-10","conditions":"Diabetes Mellitus, Type 2, Preterm Birth, Pregnancy, High Risk","enrollment":120},{"nctId":"NCT06671587","phase":"PHASE4","title":"iGlarLixi CGM Study in Chinese T2D Individuals After OADs","status":"RECRUITING","sponsor":"Sanofi","startDate":"2024-12-10","conditions":"Type 2 Diabetes (T2D)","enrollment":678},{"nctId":"NCT06762314","phase":"PHASE2","title":"Efficacy and Safety of Empagliflozin or Semaglutide in Overweight/Obese Patients With Type 1 Diabetes","status":"RECRUITING","sponsor":"Mostafa Bahaa","startDate":"2025-01-20","conditions":"Diabetes","enrollment":105},{"nctId":"NCT07461103","phase":"PHASE2","title":"Effect of Topical Insulin on Healing Rate of Pemphigus Lesions","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-06-22","conditions":"Pemphigus Vulgaris, Skin Erosion, Autoimmune Blistering Disease","enrollment":20},{"nctId":"NCT04416269","phase":"PHASE4","title":"Oral Anti Diabetic Agents in the Hospital","status":"ACTIVE_NOT_RECRUITING","sponsor":"Emory University","startDate":"2020-08-07","conditions":"Diabetes Mellitus","enrollment":255},{"nctId":"NCT01794143","phase":"PHASE3","title":"A Comparative Effectiveness Study of Major Glycemia-lowering Medications for Treatment of Type 2 Diabetes","status":"COMPLETED","sponsor":"GRADE Study Group","startDate":"2013-05","conditions":"Type 2 Diabetes, Comparative Effectiveness of Glycemia-lowering Medications","enrollment":7850},{"nctId":"NCT07173712","phase":"PHASE4","title":"Regimen Transition After Short-Term Intensive Insulin Therapy in Type 2 Diabetes","status":"NOT_YET_RECRUITING","sponsor":"Yanbing Li","startDate":"2026-03-15","conditions":"Type 2 Diabetes","enrollment":324},{"nctId":"NCT06881264","phase":"PHASE3","title":"A Study Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-04-30","conditions":"Adult Patients With Type 2 Diabetes Uncontrolled on Oral Antidiabetic Drugs","enrollment":401},{"nctId":"NCT01239550","phase":"NA","title":"Insulin Detemir in Obesity Management","status":"ACTIVE_NOT_RECRUITING","sponsor":"Vanderbilt University","startDate":"2011-04","conditions":"Diabetes, Obesity","enrollment":240},{"nctId":"NCT05803421","phase":"PHASE3","title":"A Study of Daily Oral Orforglipron (LY3502970) Compared With Insulin Glargine in Participants With Type 2 Diabetes and Obesity or Overweight at Increased Cardiovascular Risk","status":"ACTIVE_NOT_RECRUITING","sponsor":"Eli Lilly and Company","startDate":"2023-04-03","conditions":"Type 2 Diabetes, Obesity, Overweight or Obesity","enrollment":2749},{"nctId":"NCT06716424","phase":"PHASE4","title":"A Study to Investigate Safety and Efficacy of iGlarLixi in Adult Patients With Type 2 Diabetes Mellitus","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sanofi","startDate":"2025-01-06","conditions":"Type 2 Diabetes","enrollment":105},{"nctId":"NCT07336914","phase":"NA","title":"Effect of Conventional vs Intensive Management on Gestational Diabetes and Maternal Fetal Outcomes","status":"RECRUITING","sponsor":"Khyber Medical University Peshawar","startDate":"2025-10-01","conditions":"Gestational Diabetes","enrollment":60},{"nctId":"NCT06871761","phase":"PHASE3","title":"A Trial Comparing HR17031 With Insulin Glargine in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2024-05-08","conditions":"Adult Patients With Type 2 Diabetes","enrollment":393},{"nctId":"NCT07076199","phase":"PHASE3","title":"A Research Study to See How a Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine, Both in Combination With Insulin Aspart, in Adults With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2025-08-11","conditions":"Diabetes Mellitus, Type 1","enrollment":877},{"nctId":"NCT06445946","phase":"PHASE4","title":"DECIDE: A Comparative Effectiveness Trial of Metformin Versus Insulin for the Treatment of Gestational Diabetes","status":"RECRUITING","sponsor":"Ohio State University","startDate":"2024-08-01","conditions":"Gestational Diabetes Mellitus, Pregnancy, High Risk","enrollment":1572},{"nctId":"NCT04952779","phase":"","title":"Regulatory Post Marketing Surveillance (rPMS) Study of Xultophy® (Insulin Degludec/Liraglutide) to Evaluate Safety and Effectiveness in Patients With Type 2 Diabetes Mellitus in Routine Clinical Practice in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-06-02","conditions":"Diabetes Mellitus, Type 2","enrollment":750},{"nctId":"NCT07307235","phase":"PHASE4","title":"Efficacy and Safety of iGlarLixi Versus Standard of Care in a Real-world Adult China Population With Uncontrolled Type 2 Diabetes on Oral Agents","status":"NOT_YET_RECRUITING","sponsor":"Shanghai Zhongshan Hospital","startDate":"2025-12-15","conditions":"Type 2 Diabetes","enrollment":1316},{"nctId":"NCT07282054","phase":"PHASE3","title":"Efficacy and Safety of THDB0206 Compared to Insulin Lispro Injection in Participants With Type 1 Diabetes","status":"COMPLETED","sponsor":"Tonghua Dongbao Pharmaceutical Co.,Ltd","startDate":"2022-04-13","conditions":"Type 1 Diabetes","enrollment":550},{"nctId":"NCT05220917","phase":"","title":"Comparative Effectiveness and Safety of Four Second Line Pharmacological Strategies in Type 2 Diabetes Study","status":"ACTIVE_NOT_RECRUITING","sponsor":"Brigham and Women's Hospital","startDate":"2021-08-01","conditions":"Cardiovascular Events, Type2 Diabetes, Renal Disease","enrollment":781430},{"nctId":"NCT04460885","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Insulin, Insulin Icodec and an Available Insulin, Insulin Glargine, in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-11-25","conditions":"Diabetes Mellitus, Type 2","enrollment":984},{"nctId":"NCT04848480","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec, and an Available Daily Insulin, Insulin Degludec, Both in Combination With Mealtime Insulin in People With Type 1 Diabetes (ONWARDS 6)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-04-30","conditions":"Diabetes Mellitus, Type 1","enrollment":582},{"nctId":"NCT04880850","phase":"PHASE3","title":"A Research Study to Compare Two Types of Insulin, a New Weekly Insulin, Insulin Icodec and an Available Daily Insulin, Insulin Glargine, Both in Combination With Mealtime Insulin, in People With Type 2 Diabetes Who Use Daily Insulin and Mealtime Insulin (ONWARDS 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-05-14","conditions":"Diabetes Mellitus, Type 2","enrollment":582},{"nctId":"NCT07171684","phase":"NA","title":"Single vs Multi-Dose Insulin for Glycemic Control (SUGAR)","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2025-11-26","conditions":"Diabetes in Pregnancy, Gestational Diabetes","enrollment":176},{"nctId":"NCT05013229","phase":"PHASE3","title":"A Research Study to See How Well the New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Level in People With Type 2 Diabetes Compared to Insulin Glargine Taken Daily With Insulin Aspart (COMBINE 3)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":679},{"nctId":"NCT06688123","phase":"PHASE2","title":"Efficacy and Safety of SHR-3167 and Insulin Glargine in Type 2 Diabetes Subjects","status":"ACTIVE_NOT_RECRUITING","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2025-01-08","conditions":"Type 2 Diabetes","enrollment":275},{"nctId":"NCT07242664","phase":"PHASE1","title":"Clamp Study to Estimate the Relative Potency of GZR33 Versus Insulin Degludec at Steady State","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-10-13","conditions":"Type 1 Diabetes Mellitis","enrollment":12},{"nctId":"NCT06370715","phase":"PHASE4","title":"A Study of LY900014 in Adult Participants With Type 2 Diabetes Mellitus in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2024-04-18","conditions":"Diabetes Mellitus, Type 2","enrollment":150},{"nctId":"NCT05413369","phase":"PHASE3","title":"iGlarLixi vs IDegAsp in Chinese Participants After OAD(s)","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-07-07","conditions":"Type 2 Diabetes Mellitus","enrollment":582},{"nctId":"NCT06685185","phase":"PHASE1","title":"A Research Study of a New Medicine NNC0363-1063 in Healthy Participants and Participants With Type 1 Diabetes","status":"RECRUITING","sponsor":"Novo Nordisk A/S","startDate":"2024-11-12","conditions":"Diabetes Mellitus, Type 1","enrollment":154},{"nctId":"NCT05002933","phase":"PHASE4","title":"A Clinical Efficacy and Safety Study of Insulin Glargine U300 in Chinese Adult Patients With Uncontrolled Type 2 Diabetes Mellitus With a 3-month Extension Period","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-05-20","conditions":"Type 2 Diabetes Mellitus","enrollment":570},{"nctId":"NCT04980027","phase":"PHASE4","title":"Evaluation of the Safety and Efficacy of Insulin Glargine 300 U/ml (Gla-300) in Insulin-naïve Patients With Type 2 Diabetes Mellitus Uncontrolled on Oral Antihyperglycemic Drugs","status":"COMPLETED","sponsor":"Sanofi","startDate":"2021-06-07","conditions":"Type 2 Diabetes Mellitus","enrollment":228},{"nctId":"NCT07117240","phase":"PHASE4","title":"Evaluation of the Efficacy and Safety of GLP-1 Receptor Agonist Therapy In Steroid-Induced Diabetes","status":"ENROLLING_BY_INVITATION","sponsor":"Medical University of Warsaw","startDate":"2025-07-10","conditions":"Steroid-Induced Diabetes, Steroid-Induced Hyperglycemia, Diabetes","enrollment":100},{"nctId":"NCT05614089","phase":"PHASE4","title":"Human Versus Analogue Insulin for Youth With Type 1 Diabetes in Low-Resource Settings","status":"COMPLETED","sponsor":"Jing Luo","startDate":"2023-03-15","conditions":"Diabetes Mellitus, Type 1, Type 1 Diabetes","enrollment":400},{"nctId":"NCT05114590","phase":"PHASE4","title":"Effect of Soliqua 100/33 on Time in Range From Continuous Glucose Monitoring in Insulin-naive Patients With Very Uncontrolled Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Sanofi","startDate":"2022-01-27","conditions":"Type 2 Diabetes Mellitus","enrollment":124},{"nctId":"NCT05552859","phase":"PHASE4","title":"Gla-300 and IDeg-100 in Insulin-Naïve People With Type 2 Diabetes Mellitus and Renal Impairment","status":"TERMINATED","sponsor":"Sanofi","startDate":"2022-12-05","conditions":"Type 2 Diabetes Mellitus, Renal Impairment","enrollment":62},{"nctId":"NCT04760626","phase":"PHASE3","title":"A Research Study to Compare a New Weekly Insulin, Insulin Icodec Used With DoseGuide App, and Daily Insulins in People With Type 2 Diabetes Who Have Not Used Insulin Before","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2021-03-01","conditions":"Diabetes Mellitus, Type 2","enrollment":1085},{"nctId":"NCT06340854","phase":"PHASE3","title":"A Research Study to See How Switching From a Daily Basal Insulin to a New Weekly Insulin, Insulin Icodec, Helps in Reducing the Blood Sugar Compared to Daily Insulin Glargine in Adults With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-04-19","conditions":"Diabetes, Type 2","enrollment":429},{"nctId":"NCT06269107","phase":"PHASE3","title":"A Research Study to See How Well New Weekly Medicine IcoSema, Which is a Combination of Insulin Icodec and Semaglutide, Controls Blood Sugar Levels in People With Type 2 Diabetes (T2D), Compared to Daily Insulin Glargine (COMBINE 4)","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-15","conditions":"Type 2 Diabetes","enrollment":485},{"nctId":"NCT07146347","phase":"PHASE1","title":"Comparison Study of Insulin GZR4 With Insulin Degludec","status":"RECRUITING","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2025-08-15","conditions":"Type 2 Diabetes","enrollment":14},{"nctId":"NCT05662332","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) Compared to Glargine in Adult Participants With Type 2 Diabetes Who Are Starting Basal Insulin for the First Time (QWINT-1)","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2023-01-14","conditions":"Type 2 Diabetes, T2D","enrollment":795},{"nctId":"NCT05098470","phase":"PHASE3","title":"Effects of Modulators of Gluconeogenesis, Glycogenolysis and Glucokinase Activity","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Alabama at Birmingham","startDate":"2022-03-07","conditions":"Type 2 Diabetes","enrollment":100},{"nctId":"NCT06717191","phase":"PHASE4","title":"Impact of Introducing Basaglar Insulin to the Treatment Regimen of Youth With Diabetes in Pakistan","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-09","conditions":"Type 1 Diabetes","enrollment":296},{"nctId":"NCT07070752","phase":"PHASE3","title":"Evaluation of Insulin Glulisine (GP40321) Compared to Insulin Glulisine (Apidra® SoloStar®) in Type 1 Diabetes Mellitus Patients","status":"COMPLETED","sponsor":"Geropharm","startDate":"2023-04-14","conditions":"Type 1 Diabetes Mellitis","enrollment":224},{"nctId":"NCT02879409","phase":"NA","title":"HbA1c Variability in Type II Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"Weill Cornell Medical College in Qatar","startDate":"2016-11","conditions":"Diabetes Mellitus Type 2","enrollment":150},{"nctId":"NCT05790681","phase":"PHASE1","title":"A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-04-25","conditions":"Diabetes Mellitus, Type 2","enrollment":18},{"nctId":"NCT06738849","phase":"NA","title":"EkiYou-Study-2 : A National Multicentric Trial of the EkiYou Application for Insulin Bolus Calculation","status":"RECRUITING","sponsor":"DiappyMed","startDate":"2024-11-05","conditions":"Diabetes Type 1, Diabetes Type 2 on Insulin, Pancreatogenous Diabetes","enrollment":154},{"nctId":"NCT05780151","phase":"PHASE4","title":"Remote And Decentralised Innovative Approaches to Clinical Trials (RADIAL)","status":"COMPLETED","sponsor":"Mira Zuidgeest","startDate":"2023-07-10","conditions":"Diabetes Mellitus, Type 2","enrollment":107},{"nctId":"NCT06288412","phase":"PHASE1","title":"A Study to Test How a New Long-acting Insulin Works in the Body of Patients With Type 2 Diabetes During Exercise and Prolonged Fasting","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2024-02-26","conditions":"Diabetes Mellitus, Type 2","enrollment":30},{"nctId":"NCT04974528","phase":"PHASE3","title":"Afrezza® INHALE-1 Study in Pediatrics","status":"COMPLETED","sponsor":"Mannkind Corporation","startDate":"2021-09-29","conditions":"Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":319},{"nctId":"NCT05462756","phase":"PHASE3","title":"A Study of Insulin Efsitora Alfa (LY3209590) as a Weekly Basal Insulin Compared to Insulin Glargine in Adult Participants With Type 2 Diabetes on Multiple Daily Injections","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-08-11","conditions":"Type 2 Diabetes, Type 2 Diabetes Treated With Insulin","enrollment":730},{"nctId":"NCT06107153","phase":"PHASE3","title":"Effect of Short-term Basal Insulin Initiation in Newly Diagnosed Type 2 Diabetes on 1-year Glycemic Control","status":"COMPLETED","sponsor":"University of Basrah","startDate":"2023-11-01","conditions":"Type2diabetes","enrollment":243},{"nctId":"NCT02496780","phase":"PHASE2, PHASE3","title":"The Impact of Insulin Therapy on Protein Turnover in Pre-Diabetic Cystic Fibrosis Patients","status":"TERMINATED","sponsor":"University of Minnesota","startDate":"2015-08","conditions":"Cystic Fibrosis","enrollment":65},{"nctId":"NCT06256497","phase":"","title":"A Prospective Study to Evaluate Revita DMR Post Market Pilot Clinical Follow-Up Registry in Patient With Type 2 Diabetes","status":"SUSPENDED","sponsor":"Fractyl Health Inc.","startDate":"2023-06-27","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT05702073","phase":"PHASE3","title":"To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Treated With Basal Insulin.","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-31","conditions":"Type 2 Diabetes Mellitus","enrollment":423},{"nctId":"NCT05699408","phase":"PHASE3","title":"To Compare the Efficacy and Safety of INS068 and Insulin Glargine in Subjects With Type 2 Diabetes Mellitus Not Adequately Controlled With Oral Antidiabetic Drugs","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2023-03-31","conditions":"Type 2 Diabetes","enrollment":513},{"nctId":"NCT06638567","phase":"NA","title":"Postoperative Basal Bolus or Sliding Scale Insulin Regimen in DM2 and Its Effect on Surgical Site Infections.","status":"RECRUITING","sponsor":"Abraham Hulst, MD, PhD","startDate":"2025-01-03","conditions":"Diabetes Mellitus, Type 2, Surgical Site Infection","enrollment":1008},{"nctId":"NCT03087032","phase":"PHASE4","title":"Liraglutide-bolus vs Glargine-bolus Therapy in Overweight/Obese Type 2 Diabetes Patients (LiraGooD)","status":"RECRUITING","sponsor":"The First Affiliated Hospital of Xiamen University","startDate":"2019-01-10","conditions":"Type 2 Diabetes Patients, Overweight and Obesity, Hyperglycaemia (Diabetic)","enrollment":164},{"nctId":"NCT05768191","phase":"PHASE4","title":"Comparative Efficacy of a Two Daily Mixed Insulin Injection Versus a Basal-bolus Scheme With Human Insulin","status":"COMPLETED","sponsor":"Université NAZI BONI","startDate":"2023-06-15","conditions":"Type 1 Diabetes","enrollment":22},{"nctId":"NCT06419803","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes (START 2)","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT06419777","phase":"NA","title":"Strict Versus Permissive Thresholds for Initiation of Pharmacotherapy in Gestational Diabetes","status":"RECRUITING","sponsor":"Thomas Jefferson University","startDate":"2024-09-01","conditions":"Gestational Diabetes, Pregnancy Related","enrollment":430},{"nctId":"NCT06674135","phase":"PHASE4","title":"Evaluating the Impact of Introducing Basaglar, a Long-acting Analog Insulin, on Clinical and Quality of Life Outcomes in Youth with Diabetes in Bangladesh","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-06-01","conditions":"Type I Diabetes","enrollment":202},{"nctId":"NCT06650943","phase":"NA","title":"Nursing Intervention in Weight and Metabolic Syndrome Management in First-episode Psychosis (MetaKOP)","status":"RECRUITING","sponsor":"Hospital de Basurto","startDate":"2023-10-25","conditions":"First Episode Psychosis (FEP), Metabolic Syndrome X","enrollment":88},{"nctId":"NCT06624943","phase":"PHASE4","title":"Introducing Biosimilar Insulin Glargine to the Treatment Regimen of Children and Youth with Type 1 Diabetes in Mali","status":"COMPLETED","sponsor":"Life for a Child Program, Diabetes Australia","startDate":"2022-03-14","conditions":"Type 1 Diabetes (T1D)","enrollment":260},{"nctId":"NCT06619301","phase":"PHASE3","title":"RCT Glargine vs NPH for Treatment of DM in Pregnancy","status":"RECRUITING","sponsor":"Loyola University","startDate":"2024-04-01","conditions":"Diabetes Mellitus in Pregnancy, Type 2 Diabetes Mellitus (T2DM), Gestational Diabetes Mellitus, Class A2","enrollment":160},{"nctId":"NCT06592950","phase":"","title":"Patient Preference Study in Type-2 Diabetes Mellitus: Discrete Choice Experiment (DCE) to Support Novo Nordisk's Long-Acting Insulin","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2023-11-02","conditions":"Type-2 Diabetes Mellitus (T2DM)","enrollment":513},{"nctId":"NCT01107717","phase":"PHASE4","title":"Durability of Combination Therapy With Exenatide/Pioglitazone/Metformin vs. Conventional Therapy in New Onset T2DM","status":"COMPLETED","sponsor":"The University of Texas Health Science Center at San Antonio","startDate":"2009-01","conditions":"Diabetes","enrollment":318},{"nctId":"NCT06178874","phase":"NA","title":"Insulin Degludec vs Insulin Glargine for Glycemic Control in Critical Illness Hyperglycemia","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-12-01","conditions":"Glycemic Control, Insulin, Critical Illness","enrollment":90},{"nctId":"NCT04597697","phase":"PHASE1","title":"A Study to Test How a New Long-acting Insulin (Insulin Icodec) Works in the Body of People With Liver Disease","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-12-22","conditions":"Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT06007508","phase":"PHASE2","title":"Early Administration of Insulin Glargine in Patients With Diabetic Ketoacidosis","status":"TERMINATED","sponsor":"HealthPartners Institute","startDate":"2022-05-31","conditions":"DKA","enrollment":8},{"nctId":"NCT02871089","phase":"NA","title":"Closed Loop From Onset in Type 1 Diabetes","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Cambridge","startDate":"2017-01","conditions":"Diabetes Mellitus, Type 1 Diabetes","enrollment":96},{"nctId":"NCT03437330","phase":"PHASE4","title":"Empagliflozin Effect on Glucose Toxicity","status":"WITHDRAWN","sponsor":"University Hospital Tuebingen","startDate":"2021-10-27","conditions":"Type2 Diabetes Mellitus","enrollment":""},{"nctId":"NCT03371082","phase":"PHASE3","title":"Gan & Lee Insulin Glargine Target Type (1) Evaluating Research","status":"COMPLETED","sponsor":"Gan and Lee Pharmaceuticals, USA","startDate":"2017-10-31","conditions":"Diabetes Mellitus, Type 1","enrollment":576},{"nctId":"NCT03874715","phase":"PHASE3","title":"Comparison of SAR341402 to NovoLog in Adult Patients With Type 1 Diabetes Mellitus Also Using Insulin Glargine","status":"COMPLETED","sponsor":"Sanofi","startDate":"2019-03-11","conditions":"Type 1 Diabetes Mellitus","enrollment":210},{"nctId":"NCT04460326","phase":"PHASE3","title":"Novolog vs. Fiasp Insulin in Non-critically Ill Hospitalized Patients With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Boston Medical Center","startDate":"2020-12-07","conditions":"Type 2 Diabetes Treated With Insulin","enrollment":137},{"nctId":"NCT04623086","phase":"PHASE4","title":"Comparison of Glargine to Degludec Insulin Transition With or Without a Bridging Glargine Dose","status":"COMPLETED","sponsor":"University of Washington","startDate":"2020-02-14","conditions":"Type 1 Diabetes","enrollment":59},{"nctId":"NCT02048189","phase":"PHASE4","title":"Treatment With Continuous Sub-cutaneous Insulin Infusion Via a Portable Pump Versus Discontinuous Insulin Infusion Via Multiple-injections in Type 2 Diabetes","status":"TERMINATED","sponsor":"Centre Hospitalier Universitaire Dijon","startDate":"2012-03-08","conditions":"Patient With Type 2 Diabetes Treated With Insulin Using a Baseline/Bolus Strategy","enrollment":14},{"nctId":"NCT04153981","phase":"PHASE4","title":"A Study of Insulin Glargine (LY2963016) in Adult Participants With Type 2 Diabetes in India","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2019-12-16","conditions":"Type 2 Diabetes Mellitus","enrollment":304},{"nctId":"NCT04678661","phase":"NA","title":"My Dose Coach Mobile App to Support Insulin Titration and Maintenance","status":"TERMINATED","sponsor":"Linda Siminerio","startDate":"2021-02-15","conditions":"Diabetes Mellitus Type 2 - Insulin-Treated","enrollment":60},{"nctId":"NCT00455858","phase":"PHASE4","title":"Evaluation of the Glycaemic Control With Insulin Detemir as an add-on to Current Oral Anti-diabetic Drug Treatment in Subjects With Type 2 Diabetes in Korea","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-11","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":87},{"nctId":"NCT02518945","phase":"PHASE3","title":"Dapagliflozin As Additional Treatment To Liraglutide And Insulin In Patients With Type 1 Diabetes","status":"COMPLETED","sponsor":"University at Buffalo","startDate":"2015-08","conditions":"Type 1 Diabetes Mellitus","enrollment":26},{"nctId":"NCT04575181","phase":"PHASE1","title":"A Clinical Study to Compare the Efficacy and Safety of a Novel Medicine (NNC0268-0965) With Insulin Glargine","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2020-10-21","conditions":"Diabetes Mellitus, Type 2","enrollment":86},{"nctId":"NCT05596747","phase":"PHASE1","title":"A Study of LY3209590 in Chinese Participants With Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Eli Lilly and Company","startDate":"2022-11-30","conditions":"Diabetes Mellitus, Type 2","enrollment":31},{"nctId":"NCT00671008","phase":"","title":"Observational Study of Patients Using NovoMix® 30 or Levemir® for Treatment of Type 1 or Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-12","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":400},{"nctId":"NCT00383877","phase":"PHASE3","title":"Effect of Insulin Detemir on Blood Glucose Control in Subjects With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-09","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":263},{"nctId":"NCT00447382","phase":"PHASE3","title":"Safety of Insulin Detemir Produced by a New Process as Measured by Antibody Formation in Subjects With Type 1 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-03","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":330},{"nctId":"NCT01524705","phase":"PHASE4","title":"FLuctuATion Reduction With inSULin and Glp-1 Added togetheR (FLAT-SUGAR)","status":"COMPLETED","sponsor":"University of Washington","startDate":"2012-08","conditions":"Type 2 Diabetes","enrollment":102},{"nctId":"NCT05360537","phase":"PHASE4","title":"Effects of Degludec/Liraglutide on Time in Range, Inflammation and Endothelial Function vs Insulin Basal Bolus in Diabetic Inpatients","status":"COMPLETED","sponsor":"University of Palermo","startDate":"2021-04-01","conditions":"Diabetes Mellitus, Type 2","enrollment":100},{"nctId":"NCT03660553","phase":"PHASE4","title":"Simplified Insulin Regimen for the Elderly","status":"TERMINATED","sponsor":"University of Miami","startDate":"2018-10-10","conditions":"Type 2 Diabetes Mellitus","enrollment":7},{"nctId":"NCT00655200","phase":"","title":"Observational Study of Safety and Tolerability of Levemir™ FlexPen™ (Insulin Detemir) in the Treatment of Type 1 and Type 2 Diabetes Mellitus","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-02","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":2286},{"nctId":"NCT06127433","phase":"PHASE4","title":"The Effect of Short-term Insulin Intensive Therapy Based on the Application of Insulin Pump and Real-time Dynamic Glucose Monitoring Technology on Reversing the Newly Diagnosed Type 2 Diabetes","status":"UNKNOWN","sponsor":"Sun Yat-sen University","startDate":"2023-03-07","conditions":"Insulin Pump，Continuous Glucose Monitoring Technology","enrollment":210},{"nctId":"NCT00313742","phase":"PHASE4","title":"The Effect of Exercise on Blood Glucose Levels in Patients With Type 1 Diabetes: A Comparison of 3 Long-acting Insulins","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-04","conditions":"Diabetes, Diabetes Mellitus, Type 1","enrollment":51},{"nctId":"NCT00504673","phase":"PHASE3","title":"Comparison of Insulin Detemir Versus Insulin NPH on Weight Change in Overweight and Obese With Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2005-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":277},{"nctId":"NCT00521690","phase":"PHASE4","title":"The Effect of Insulin Detemir on Blood Glucose Control in Taiwanese Patients With Type 2 Diabetes Failing on OAD","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2006-12","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":25},{"nctId":"NCT00687063","phase":"","title":"Observational Study of Safety and Efficacy of Levemir® in Type 2 Diabetes","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2008-04","conditions":"Diabetes, Diabetes Mellitus, Type 2","enrollment":10008},{"nctId":"NCT00701155","phase":"","title":"Observational Study to Evaluate the Safety While Using Levemir®","status":"COMPLETED","sponsor":"Novo Nordisk A/S","startDate":"2007-07","conditions":"Diabetes, Diabetes Mellitus, Type 1, Diabetes Mellitus, Type 2","enrollment":3593},{"nctId":"NCT05457933","phase":"PHASE4","title":"Efficacy and Safety of Dapagliflozin for the Hospital Management of Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Medanta, The Medicity, India","startDate":"2022-07-29","conditions":"Type2diabetes, Coronary Artery Disease","enrollment":250},{"nctId":"NCT05373186","phase":"PHASE1","title":"A Trial Investigating the Pharmacodynamics of BC Combo THDB0207 Compared With Humalog® Mix25 and Simultaneous Injections of Humalog® and Lantus® in Healthy Chinese Volunteers","status":"COMPLETED","sponsor":"Adocia","startDate":"2022-05-12","conditions":"Healthy","enrollment":27},{"nctId":"NCT02408120","phase":"PHASE4","title":"Benefits of Insulin Supplementation for Correction of Hyperglycemia in Patients With Type 2 Diabetes","status":"COMPLETED","sponsor":"Emory University","startDate":"2015-10","conditions":"Diabetes Mellitus, Type 2","enrollment":226},{"nctId":"NCT05579119","phase":"PHASE4","title":"SITAgliptin Plus GLARgine to Glycemic Control in the Hospital Setting (SITAGLAR-H)","status":"COMPLETED","sponsor":"Hospital de Especialidades, Centro Medico Nacional \"La Raza\", Instituto Mexicano del Seguro Social","startDate":"2022-07-06","conditions":"Type 2 Diabetes","enrollment":76},{"nctId":"NCT05124457","phase":"PHASE2","title":"DETERMINE: Detemir vs NPH","status":"RECRUITING","sponsor":"University of California, Los Angeles","startDate":"2022-02-01","conditions":"Gestational Diabetes, Diabetes Mellitus, Type 2","enrollment":336}],"_emaApprovals":[],"_faersSignals":[{"count":13,"reaction":"BLOOD GLUCOSE INCREASED"},{"count":10,"reaction":"DRUG INEFFECTIVE"},{"count":7,"reaction":"CARDIAC FAILURE CONGESTIVE"},{"count":7,"reaction":"DIARRHOEA"},{"count":7,"reaction":"DYSPNOEA"},{"count":7,"reaction":"WEIGHT INCREASED"},{"count":6,"reaction":"FATIGUE"},{"count":6,"reaction":"HYPOGLYCAEMIA"},{"count":6,"reaction":"HYPOTENSION"},{"count":5,"reaction":"ABDOMINAL PAIN"}],"_approvalHistory":[],"publicationCount":1209,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["Glargine"],"phase":"marketed","status":"active","brandName":"Long acting insulin","genericName":"Long acting insulin","companyName":"Ain Shams University","companyId":"ain-shams-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Long-acting insulin provides sustained glucose control by mimicking the body's basal insulin secretion over an extended period. Used for Type 1 diabetes mellitus, Type 2 diabetes mellitus.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":2,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}